Literature DB >> 17222362

[Establishment and biological characteristics of lung cancer cell line XWLC-05].

Feng-Cai Yan1, Qin-Qin Wang, Yong-Hua Ruan, Li-Ju Ma, Jian-Tao Jia, Ke-Wei Jin.   

Abstract

BACKGROUND &
OBJECTIVE: The incidence of lung cancer is high at Xuanwei, Yunnan Province, at where the mortality rate of this disease in women is the highest in China. This study was to establish a Xuanwei woman lung adenocarcinoma cell line, and provide an in vitro experimental model for the study of preventing and treating lung cancer.
METHODS: The cells derived from a surgical specimen of a woman patient with lung cancer were primarily cultured. The biological characteristics of the cell line were studied with light and electron microscopes, determination of doubling time and growth curve, culturing in soft agar, flow cytometry (FCM), chromosome and G-band detection, c-12 multiple tumor markers detection, and inoculation in mice.
RESULTS: Morphologic study, proliferation dynamics, and invasive growth showed that the cultured cells have malignant characteristics. Their chromosome numbers ranged from 55 to 69, with a mode number of 60-63. The tumor formation rate in mice was 100% after axillary transplantation of the cells; the morphology of the tumor cells was similar to that of the pathologic specimen of the patient. The cell line was named XWLC-05.
CONCLUSION: According to the newest rules of establishing a cell line in vitro, XWLC-05 is proved to be a new cell line of human lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222362

Source DB:  PubMed          Journal:  Ai Zheng


  8 in total

1.  Sulforaphane-induced apoptosis in Xuanwei lung adenocarcinoma cell line XWLC-05.

Authors:  Lan Zhou; Qian Yao; Yan Li; Yun-Chao Huang; Hua Jiang; Chuan-Qiong Wang; Lei Fan
Journal:  Thorac Cancer       Date:  2016-11-23       Impact factor: 3.500

2.  Interleukin-1β-mediated suppression of microRNA-101 and upregulation of enhancer of zeste homolog 2 is involved in particle-induced lung cancer.

Authors:  You-Ming Lei; Yun-Fen Zu; Jiying Wang; Song Bai; Yun-Fei Shi; Rou Shi; Jin Duan; Daolei Cui; Jianlan Chen; Yang Xiang; Jian Dong
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

3.  Different Proteins Regulated Apoptosis, Proliferation and Metastasis of Lung Adenocarcinoma After Radiotherapy at Different Time.

Authors:  P L Dai; X S Du; Y Hou; L Li; Y X Xia; L Wang; H X Chen; L Chang; W H Li
Journal:  Cancer Manag Res       Date:  2020-04-02       Impact factor: 3.989

4.  Effects and mechanism of microRNA‑218 against lung cancer.

Authors:  Yan Chen; Ji-Lin Yang; Zhen-Zhen Xue; Qiu-Chen Cai; Chun Hou; Hong-Juan Li; Liu-Xin Zhao; Yin Zhang; Cheng-Wei Gao; Li Cong; Tian-Zuo Wang; Dong-Mei Chen; Guo-Sheng Li; Shi-Qing Luo; Qian Yao; Chan-Juan Yang; Qi-Shun Zhu; Chuan-Hai Cao
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

5.  Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLC‑05 lung cancer cells.

Authors:  Quan Gong; Chao Liu; Cunde Wang; Li Zhuang; Lijuan Zhang; Xicai Wang
Journal:  Mol Med Rep       Date:  2017-11-03       Impact factor: 2.952

6.  [Establishment of Orthotopic Xuanwei lung cancer SCID mouse model and analysis of biological properties].

Authors:  Yongchun Zhou; Yan Chen; Xicai Wang; Xin Liu; Hutao Shi; Qian Yao; Congguo Jin; Zhiping Wu; Yunchao Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-08

7.  [Expression and clinical significance of the thyroid transcription factor 1 in Xuanwei lung adenocarcinoma].

Authors:  Yunfen Zu; Xicai Wang; Xin Liu; Yan Chen; Chengwen Li; Xueqin Shang; Yucheng Xie; Hongyuan Zhao; Jiying Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-03

8.  Targeted silencing of TEM8 suppresses non‑small cell lung cancer tumor growth via the ERK/Bcl‑2 signaling pathway.

Authors:  Quan Gong; Jing Deng; Lijuan Zhang; Chunyan Zhou; Chaojiang Fu; Xicai Wang; Li Zhuang
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.